文献速递头颈与中枢神经肿瘤支持与姑息治疗

身体成分对晚期头颈癌复发和生存的预后价值

Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer.
PubMed 文献 · Eur J Cancer · 2019-06-10

这项前瞻性研究纳入258例接受根治性治疗的晚期头颈鳞癌患者,在治疗前后通过PET/CT测量第三腰椎水平骨骼肌横截面积等身体成分指标。结果显示治疗前后肌肉减少症分别见于6.6%和12.4%的患者,且治疗前后存在肌肉减少症者总体复发或死亡风险约增加三倍。

要点

  • 晚期头颈鳞癌患者治疗前后肌肉减少症与复发和生存独立相关。
  • 治疗前后存在肌肉减少症者总体复发或死亡风险约增加三倍。
  • 治疗后骨骼肌指数、内脏脂肪面积、瘦体重、脂肪量和BMI均显著下降。

核心结论

  • 骨骼肌质量减少可能预测晚期头颈鳞癌患者根治性治疗后的复发和生存。

研究设计与样本

  • 前瞻性队列研究,纳入258例接受根治性治疗的晚期头颈鳞癌连续患者。
  • 治疗前后通过全身18F-FDG PET/CT在第三腰椎水平测量骨骼肌横截面积以判定肌肉减少症。
  • 采用单因素和多因素Cox比例风险回归分析无病生存期和总生存期的预后因素。

主要发现

  • 治疗前和治疗后肌肉减少症分别见于17例(6.6%)和32例(12.4%)患者。
  • 治疗后骨骼肌指数、内脏脂肪面积、瘦体重、脂肪量和体重指数均显著下降(均P < 0.05)。
  • 多因素分析显示年龄、Charlson合并症指数、治疗前后肌肉减少症、治疗前低白蛋白血症、p16状态和肿瘤部位是无病生存期和总生存期的独立预测变量(均P < 0.05)。
  • 治疗前后存在肌肉减少症的患者总体复发或死亡风险约增加三倍。

临床怎么用

  • 在晚期头颈鳞癌根治性治疗前后评估骨骼肌质量,有助于识别复发和死亡高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is commonly associated with a high risk of malnutrition and sarcopenia, related to adverse clinical outcomes. This study evaluated the prognostic values of body composition on recurrence and survival in patients with advanced-stage HNSCC. METHODS: This study prospectively enrolled 258 consecutive patients with definitive treatments for advanced-stage HNSCC. For the determination of sarcopenia, the cross-sectional area of the skeletal muscles (SMs) was measured at the level of the third lumbar vertebra on the computed tomography images of whole-body 18F-fluorodeoxyglucose positron-emission tomography/computed tomography before and after treatments. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify the prognostic factors of disease-free survival (DFS) and overall survival (OS). RESULTS: Pretreatment and post-treatment diminished SM masses (sarcopenia) were found in 17 (6.6%) and 32 (12.4%) of 258 included patients, respectively. All values of body composition, SM index, visceral fat area, lean body mass, fat mass and body mass index significantly decreased after treatment (all P < 0.05). Multivariable analyses showed that age, Charlson comorbidity index, pretreatment and post-treatment sarcopenia, pretreatment hypoalbuminaemia, p16 status and tumour site remained the independent variables predictive of DFS and OS outcomes (all P < 0.05). Patients with sarcopenia before or after treatment had about threefold increased risk of overall recurrence or death. CONCLUSION: Diminished SM mass may predict recurrence and survival after definitive treatments in patients with advanced-stage HNSCC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jung AR, Roh JL, Kim JS, et al. Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer. Eur J Cancer. 2019. PMID: 31185387. doi:10.1016/j.ejca.2019.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。